{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,28]],"date-time":"2026-10-28T17:41:23Z","timestamp":1793209283820,"version":"4.5.0"},"reference-count":78,"publisher":"Springer Science and Business Media LLC","issue":"4","license":[{"start":{"date-parts":[[2026,2,21]],"date-time":"2026-02-21T00:00:00Z","timestamp":1771632000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2026,2,21]],"date-time":"2026-02-21T00:00:00Z","timestamp":1771632000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Ann Hematol"],"DOI":"10.1007\/s00277-026-06775-x","type":"journal-article","created":{"date-parts":[[2026,2,21]],"date-time":"2026-02-21T07:14:50Z","timestamp":1771658090000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":4,"title":["Mechanisms of resistance to bruton\u2019s tyrosine kinase inhibitors: synergistic effects of tumor microenvironment regulation and signaling pathways"],"prefix":"10.1007","volume":"105","author":[{"given":"Xinyu","family":"Dong","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shujun","family":"Tang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Miaohong","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qiuni","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yifan","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuye","family":"Shi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuan","family":"Deng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yue","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhengmei","family":"He","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Liang","family":"Yu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chunling","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,2,21]]},"reference":[{"issue":"4","key":"6775_CR1","doi-asserted-by":"crossref","first-page":"833","DOI":"10.1038\/leu.2015.316","volume":"30","author":"S Chen","year":"2016","unstructured":"Chen S, Chang BY, Chang S et al (2016) BTK Inhibition results in impaired CXCR4 chemokine receptor surface expression, signaling and function in chronic lymphocytic leukemia[J]. Leukemia 30(4):833\u2013843","journal-title":"Leukemia"},{"issue":"20","key":"6775_CR2","doi-asserted-by":"crossref","first-page":"4642","DOI":"10.1158\/1078-0432.CCR-15-0781","volume":"21","author":"SEM Herman","year":"2015","unstructured":"Herman SEM, Mustafa RZ, Jones J et al (2015) Treatment with ibrutinib inhibits BTK- and VLA-4-Dependent adhesion of chronic lymphocytic leukemia cells in Vivo[J]. Clin Cancer Res 21(20):4642\u20134651","journal-title":"Clin Cancer Res"},{"key":"6775_CR3","volume":"12","author":"M Xiao","year":"2021","unstructured":"Xiao M, He J, Yin L et al (2021) Tumor-associated macrophages: critical players in drug resistance of breast cancer. Front Immunol 12:799428","journal-title":"Front Immunol"},{"issue":"18","key":"6775_CR4","doi-asserted-by":"crossref","first-page":"3612","DOI":"10.1158\/1078-0432.CCR-22-3217","volume":"29","author":"A Alsadhan","year":"2023","unstructured":"Alsadhan A, Chen J, Gaglione EM et al (2023) CD49d expression identifies a biologically distinct subtype of chronic lymphocytic leukemia with inferior progression-free survival on BTK inhibitor therapy. Clin Cancer Res 29(18):3612\u20133621","journal-title":"Clin Cancer Res"},{"issue":"3","key":"6775_CR5","doi-asserted-by":"crossref","first-page":"224","DOI":"10.1038\/s41388-022-02540-2","volume":"42","author":"W Zeng","year":"2023","unstructured":"Zeng W, Xiong L, Wu W et al (2023) CCL18 signaling from tumor-associated macrophages activates fibroblasts to adopt a chemoresistance-inducing phenotype[J]. Oncogene 42(3):224\u2013237","journal-title":"Oncogene"},{"issue":"7","key":"6775_CR6","doi-asserted-by":"crossref","first-page":"399","DOI":"10.1038\/nrclinonc.2016.217","volume":"14","author":"A Mantovani","year":"2017","unstructured":"Mantovani A, Marchesi F, Malesci A et al (2017) Tumour-associated macrophages as treatment targets in oncology. Nat Rev Clin Oncol 14(7):399\u2013416","journal-title":"Nat Rev Clin Oncol"},{"issue":"40","key":"6775_CR7","doi-asserted-by":"crossref","first-page":"65968","DOI":"10.18632\/oncotarget.11782","volume":"7","author":"S Fiorcari","year":"2016","unstructured":"Fiorcari S, Maffei R, Audrito V et al (2016) Ibrutinib modifies the function of monocyte\/macrophage population in chronic lymphocytic leukemia[J]. Oncotarget 7(40):65968\u201365981","journal-title":"Oncotarget"},{"key":"6775_CR8","volume":"9","author":"S Zhu","year":"2021","unstructured":"Zhu S, Gokhale S, Jung J et al (2021) Multifaceted immunomodulatory effects of the BTK inhibitors ibrutinib and acalabrutinib on different immune cell subsets - beyond B lymphocytes. Front Cell Dev Biol 9:727531","journal-title":"Front Cell Dev Biol"},{"issue":"10","key":"6775_CR9","doi-asserted-by":"crossref","first-page":"2442","DOI":"10.1038\/s41375-019-0463-3","volume":"33","author":"A Papin","year":"2019","unstructured":"Papin A, Tessoulin B, Bellanger C et al (2019) CSF1R and BTK inhibitions as novel strategies to disrupt the dialog between mantle cell lymphoma and macrophages. Leukemia 33(10):2442\u20132453","journal-title":"Leukemia"},{"key":"6775_CR10","first-page":"484","volume":"20","author":"Y Ma","year":"2021","unstructured":"Ma Y, Wu T, Ling C et al (2021) M2 macrophage-derived exosomal microRNA-155-5p promotes the immune escape of colon cancer by downregulating ZC3H12B. Mol Ther 20:484\u2013498","journal-title":"Mol Ther"},{"issue":"8","key":"6775_CR11","doi-asserted-by":"crossref","first-page":"979","DOI":"10.1007\/s00262-017-1966-2","volume":"66","author":"M Kortylewski","year":"2017","unstructured":"Kortylewski M, Moreira D (2017) Myeloid cells as a target for oligonucleotide therapeutics: turning obstacles into opportunities. Cancer Immunol Immunother 66(8):979\u2013988","journal-title":"Cancer Immunol Immunother"},{"issue":"11","key":"6775_CR12","doi-asserted-by":"crossref","first-page":"2808","DOI":"10.1182\/bloodadvances.2025016006","volume":"9","author":"JT Yoon","year":"2025","unstructured":"Yoon JT, Zhou Y, Mikhaleva M et al (2025) Characteristics and outcomes of patients with double refractory and double exposed chronic lymphocytic leukemia. Blood Adv 9(11):2808\u20132817","journal-title":"Blood Adv"},{"issue":"10","key":"6775_CR13","doi-asserted-by":"publisher","first-page":"e177054","DOI":"10.1172\/jci.insight.177054","volume":"9","author":"AL Smith","year":"2024","unstructured":"Smith AL, Skupa SA, Eiken AP et al (2024) Bet inhibition reforms the immune microenvironment and alleviates T cell dysfunction in chronic lymphocytic leukemia. JCI Insight 9(10):e177054. https:\/\/doi.org\/10.1172\/jci.insight.177054","journal-title":"JCI Insight"},{"key":"6775_CR14","doi-asserted-by":"crossref","first-page":"1201415","DOI":"10.3389\/fimmu.2023.1201415","volume":"14","author":"L Li","year":"2023","unstructured":"Li L, Zhao M, Kiernan CH et al (2023) Ibrutinib directly reduces CD8\u2009+\u2009T cell exhaustion independent of BTK[J]. Front Immunol 14:1201415","journal-title":"Front Immunol"},{"key":"6775_CR15","volume":"13","author":"Y Liu","year":"2022","unstructured":"Liu Y, Song Y, Yin Q (2022) Effects of ibrutinib on T-cell immunity in patients with chronic lymphocytic leukemia. Front Immunol 13:962552","journal-title":"Front Immunol"},{"issue":"4","key":"6775_CR16","doi-asserted-by":"crossref","first-page":"960","DOI":"10.1038\/leu.2017.304","volume":"32","author":"K Kondo","year":"2018","unstructured":"Kondo K, Shaim H, Thompson PA et al (2018) Ibrutinib modulates the immunosuppressive CLL microenvironment through STAT3-mediated suppression of regulatory B-cell function and Inhibition of the PD-1\/PD-L1 pathway[J]. Leukemia 32(4):960\u2013970","journal-title":"Leukemia"},{"issue":"4","key":"6775_CR17","doi-asserted-by":"crossref","first-page":"968","DOI":"10.3324\/haematol.2019.238154","volume":"106","author":"BS Hanna","year":"2021","unstructured":"Hanna BS, Yazdanparast H, Demerdash Y et al (2021) Combining ibrutinib and checkpoint Blockade improves CD8\u2009+\u2009T-cell function and control of chronic lymphocytic leukemia in Em-TCL1 mice[J]. Haematologica 106(4):968\u2013977","journal-title":"Haematologica"},{"key":"6775_CR18","doi-asserted-by":"publisher","unstructured":"Caserta S, Martino EA, Vigna E et al (2025) Bruton tyrosine kinase inhibitors in mantle cell lymphoma: what are the current options? Eur J Haematol 115(6):513\u2013619. https:\/\/doi.org\/10.1111\/ejh.70036","DOI":"10.1111\/ejh.70036"},{"key":"6775_CR19","doi-asserted-by":"crossref","DOI":"10.3389\/fbioe.2023.1152207","volume":"11","author":"V Tilotta","year":"2023","unstructured":"Tilotta V, Vadal\u00e0 G, Ambrosio L et al (2023) Mesenchymal stem cell-derived secretome enhances nucleus pulposus cell metabolism and modulates extracellular matrix gene expression in vitro. Front Bioeng Biotechnol 11:1152207","journal-title":"Front Bioeng Biotechnol"},{"issue":"5","key":"6775_CR20","doi-asserted-by":"crossref","first-page":"1525","DOI":"10.1007\/s12015-022-10369-1","volume":"18","author":"D Jovic","year":"2022","unstructured":"Jovic D, Yu Y, Wang D et al (2022) A brief overview of global trends in MSC-based cell therapy. Stem Cell Rev Rep 18(5):1525\u20131545","journal-title":"Stem Cell Rev Rep"},{"issue":"12","key":"6775_CR21","first-page":"1036","volume":"38","author":"L Wu","year":"2017","unstructured":"Wu L, Zhang YZ, Xia B et al (2017) [Ibrutinib inhibits mesenchymal stem cells-mediated drug resistance in diffuse large B-cell lymphoma][J]. Zhonghua Xue Ye Xue Za Zhi 38(12):1036\u20131042","journal-title":"Zhonghua Xue Ye Xue Za Zhi"},{"issue":"5","key":"6775_CR22","doi-asserted-by":"crossref","first-page":"1090","DOI":"10.1158\/1535-7163.MCT-17-0784","volume":"17","author":"J Guan","year":"2018","unstructured":"Guan J, Huang D, Yakimchuk K et al (2018) p110\u03b1 inhibition overcomes stromal cell-mediated ibrutinib resistance in mantle cell lymphoma. Mol Cancer Ther 17(5):1090\u20131100","journal-title":"Mol Cancer Ther"},{"issue":"1","key":"6775_CR23","doi-asserted-by":"crossref","first-page":"116","DOI":"10.3324\/haematol.2017.177162","volume":"103","author":"M Rudelius","year":"2018","unstructured":"Rudelius M, Rosenfeldt MT, Leich E et al (2018) Inhibition of focal adhesion kinase overcomes resistance of mantle cell lymphoma to ibrutinib in the bone marrow microenvironment[J]. Haematologica 103(1):116\u2013125","journal-title":"Haematologica"},{"issue":"1","key":"6775_CR24","doi-asserted-by":"crossref","first-page":"19906","DOI":"10.1038\/s41598-024-71054-6","volume":"14","author":"A\u00c9 Silva-Carvalho","year":"2024","unstructured":"Silva-Carvalho A\u00c9, Bispo ECI, Da Silva I G M et al (2024) Characterization of ibrutinib\u2019s effects on the morphology, proliferation, phenotype, viability, and anti-inflammatory potential of adipose-derived mesenchymal stromal cells[J]. Sci Rep 14(1):19906","journal-title":"Sci Rep"},{"issue":"8","key":"6775_CR25","doi-asserted-by":"crossref","first-page":"544","DOI":"10.1038\/s41568-023-00591-5","volume":"23","author":"Q Zeng","year":"2023","unstructured":"Zeng Q, Mousa M, Nadukkandy AS et al (2023) Understanding tumour endothelial cell heterogeneity and function from single-cell omics[J]. Nat Rev Cancer 23(8):544\u2013564","journal-title":"Nat Rev Cancer"},{"issue":"12","key":"6775_CR26","doi-asserted-by":"crossref","first-page":"e113910","DOI":"10.1371\/journal.pone.0113910","volume":"9","author":"H Ohmura-Kakutani","year":"2014","unstructured":"Ohmura-Kakutani H, Akiyama K, Maishi N et al (2014) Identification of tumor endothelial cells with high aldehyde dehydrogenase activity and a highly angiogenic phenotype[J]. PLoS ONE 9(12):e113910","journal-title":"PLoS ONE"},{"key":"6775_CR27","doi-asserted-by":"crossref","DOI":"10.3389\/fphar.2024.1384721","volume":"15","author":"D Ribatti","year":"2024","unstructured":"Ribatti D (2024) Aberrant tumor vasculature. Facts and pitfalls. Front Pharmacol 15:1384721","journal-title":"Front Pharmacol"},{"key":"6775_CR28","volume":"7","author":"M Morimoto","year":"2024","unstructured":"Morimoto M, Maishi N, Hida K (2024) Acquisition of drug resistance in endothelial cells by tumor-derived extracellular vesicles and cancer progression. Cancer Drug Resist 7:1","journal-title":"Cancer Drug Resist"},{"issue":"9","key":"6775_CR29","doi-asserted-by":"publisher","first-page":"1876","DOI":"10.3390\/pharmaceutics14091876","volume":"14","author":"J Liu","year":"2022","unstructured":"Liu J, Liu Z, Zhang J et al (2022) Ibrutinib inhibits angiogenesis and tumorigenesis in a BTK-independent manner. Pharmaceutics 14(9):1876. https:\/\/doi.org\/10.3390\/pharmaceutics14091876","journal-title":"Pharmaceutics"},{"key":"6775_CR30","volume":"6","author":"E Henke","year":"2019","unstructured":"Henke E, Nandigama R, Erg\u00fcn S (2019) Extracellular Matrix in the tumor microenvironment and its impact on cancer therapy. Front Mol Biosci 6:160","journal-title":"Front Mol Biosci"},{"issue":"12","key":"6775_CR31","doi-asserted-by":"crossref","first-page":"1243","DOI":"10.15252\/embr.201439246","volume":"15","author":"MW Pickup","year":"2014","unstructured":"Pickup MW, Mouw JK, Weaver VM (2014) The extracellular matrix modulates the hallmarks of cancer. EMBO Rep 15(12):1243\u20131253","journal-title":"EMBO Rep"},{"key":"6775_CR32","doi-asserted-by":"publisher","unstructured":"Noguchi S, Saito A, Nagase T (2018) YAP\/TAZ signaling as a molecular link between fibrosis and cancer. Int J Mol Sci 19(11):3674. https:\/\/doi.org\/10.3390\/ijms19113674","DOI":"10.3390\/ijms19113674"},{"issue":"4","key":"6775_CR33","doi-asserted-by":"crossref","first-page":"395","DOI":"10.1083\/jcb.201102147","volume":"196","author":"P Lu","year":"2012","unstructured":"Lu P, Weaver VM, Werb Z (2012) The extracellular matrix: a dynamic niche in cancer progression. J Cell Biol 196(4):395\u2013406","journal-title":"J Cell Biol"},{"issue":"1","key":"6775_CR34","doi-asserted-by":"crossref","first-page":"259","DOI":"10.1111\/imr.12978","volume":"302","author":"R Mhaidly","year":"2021","unstructured":"Mhaidly R, Mechta-Grigoriou F (2021) Role of cancer-associated fibroblast subpopulations in immune infiltration, as a new means of treatment in cancer. Immunol Rev 302(1):259\u2013272","journal-title":"Immunol Rev"},{"key":"6775_CR35","volume":"15","author":"X Feng","year":"2024","unstructured":"Feng X, Cao F, Wu X et al (2024) Targeting extracellular matrix stiffness for cancer therapy. Front Immunol 15:1467602","journal-title":"Front Immunol"},{"issue":"1","key":"6775_CR36","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1016\/j.cmet.2015.12.006","volume":"23","author":"NN Pavlova","year":"2016","unstructured":"Pavlova NN, Thompson CB (2016) The emerging hallmarks of cancer metabolism. Cell Metab 23(1):27\u201347","journal-title":"Cell Metab"},{"issue":"22","key":"6775_CR37","doi-asserted-by":"crossref","first-page":"1879","DOI":"10.1182\/blood.2023020142","volume":"142","author":"Y Liu","year":"2023","unstructured":"Liu Y, Kimpara S, Hoang NM et al (2023) EGR1-mediated metabolic reprogramming to oxidative phosphorylation contributes to ibrutinib resistance in B-cell lymphoma[J]. Blood 142(22):1879\u20131894","journal-title":"Blood"},{"issue":"6717","key":"6775_CR38","doi-asserted-by":"crossref","first-page":"l5361","DOI":"10.1126\/science.adl5361","volume":"386","author":"RC Sarott","year":"2024","unstructured":"Sarott RC, Gourisankar S, Karim B et al (2024) Relocalizing transcriptional kinases to activate apoptosis[J]. Science 386(6717):5361","journal-title":"Science"},{"issue":"24","key":"6775_CR39","doi-asserted-by":"publisher","first-page":"6054","DOI":"10.3390\/cancers14246054","volume":"14","author":"BP Bui","year":"2022","unstructured":"Bui BP, Nguyen PL, Lee K et al (2022) Hypoxia-inducible factor-1: a novel therapeutic target for the management of cancer, drug resistance, and cancer-related pain. Cancers (Basel) 14(24):6054. https:\/\/doi.org\/10.3390\/cancers14246054","journal-title":"Cancers (Basel)"},{"issue":"1","key":"6775_CR40","doi-asserted-by":"crossref","first-page":"70","DOI":"10.1038\/s41392-023-01332-8","volume":"8","author":"Z Chen","year":"2023","unstructured":"Chen Z, Han F, Du Y et al (2023) Hypoxic microenvironment in cancer: molecular mechanisms and therapeutic interventions[J]. Signal Transduct Target Ther 8(1):70","journal-title":"Signal Transduct Target Ther"},{"key":"6775_CR41","doi-asserted-by":"crossref","first-page":"1037716","DOI":"10.3389\/fgene.2022.1037716","volume":"13","author":"C Liu","year":"2022","unstructured":"Liu C, Liu L (2022) Hypoxia-related tumor environment correlated with immune infiltration and therapeutic sensitivity in diffuse large B-cell lymphoma[J]. Front Genet 13:1037716","journal-title":"Front Genet"},{"key":"6775_CR42","doi-asserted-by":"crossref","first-page":"1353787","DOI":"10.3389\/fimmu.2024.1353787","volume":"15","author":"A Nicolini","year":"2024","unstructured":"Nicolini A, Ferrari P (2024) Involvement of tumor immune microenvironment metabolic reprogramming in colorectal cancer progression, immune escape, and response to immunotherapy[J]. Front Immunol 15:1353787","journal-title":"Front Immunol"},{"key":"6775_CR43","doi-asserted-by":"publisher","unstructured":"Wang JX, Choi SYC, Niu X et al (2020) Lactic acid and an acidic tumor microenvironment suppress anticancer immunity. Int J Mol Sci 21(21):8363. https:\/\/doi.org\/10.3390\/ijms21218363","DOI":"10.3390\/ijms21218363"},{"key":"6775_CR44","doi-asserted-by":"crossref","unstructured":"Kalluri R, LeBleu VS (2020) The biology, function, and biomedical applications of exosomes[J]. Science 367(6478):6977","DOI":"10.1126\/science.aau6977"},{"key":"6775_CR45","doi-asserted-by":"crossref","first-page":"110322","DOI":"10.1016\/j.abb.2025.110322","volume":"766","author":"H Ling","year":"2025","unstructured":"Ling H, Li Y, Wang P et al (2025) Diffuse large B-cell lymphoma cell-derived Exosomal NSUN2 stabilizes PDL1 to promote tumor immune escape and M2 macrophage polarization in a YBX1-dependent manner[J]. Arch Biochem Biophys 766:110322","journal-title":"Arch Biochem Biophys"},{"issue":"6","key":"6775_CR46","doi-asserted-by":"crossref","first-page":"513","DOI":"10.1080\/13543784.2018.1482273","volume":"27","author":"K Valla","year":"2018","unstructured":"Valla K, Flowers CR, Koff JL (2018) Targeting the B cell receptor pathway in non-Hodgkin lymphoma[J]. Expert Opin Investig Drugs 27(6):513\u2013522","journal-title":"Expert Opin Investig Drugs"},{"issue":"8","key":"6775_CR47","doi-asserted-by":"crossref","first-page":"735","DOI":"10.1056\/NEJMoa2114110","volume":"386","author":"E Wang","year":"2022","unstructured":"Wang E, Mi X, Thompson MC et al (2022) Mechanisms of resistance to noncovalent bruton\u2019s tyrosine kinase Inhibitors[J]. N Engl J Med 386(8):735\u2013743","journal-title":"N Engl J Med"},{"issue":"1","key":"6775_CR48","doi-asserted-by":"crossref","first-page":"80","DOI":"10.1001\/jamaoncol.2014.218","volume":"1","author":"KJ Maddocks","year":"2015","unstructured":"Maddocks KJ, Ruppert AS, Lozanski G et al (2015) Etiology of ibrutinib therapy discontinuation and outcomes in patients with chronic lymphocytic Leukemia[J]. JAMA Oncol 1(1):80\u201387","journal-title":"JAMA Oncol"},{"issue":"42","key":"6775_CR49","doi-asserted-by":"crossref","first-page":"68833","DOI":"10.18632\/oncotarget.11932","volume":"7","author":"S Sharma","year":"2016","unstructured":"Sharma S, Galanina N, Guo A et al (2016) Identification of a structurally novel BTK mutation that drives ibrutinib resistance in CLL. Oncotarget 7(42):68833\u201368841","journal-title":"Oncotarget"},{"key":"6775_CR50","doi-asserted-by":"crossref","first-page":"504","DOI":"10.1182\/blood-2019-127674","volume":"134","author":"J Woyach","year":"2019","unstructured":"Woyach J, Huang Y, Rogers K et al (2019) Resistance to acalabrutinib in CLL is mediated primarily by BTK Mutations[J]. Blood 134:504","journal-title":"Blood"},{"issue":"10","key":"6775_CR51","doi-asserted-by":"crossref","first-page":"1061","DOI":"10.1182\/blood.2023023659","volume":"144","author":"JA Woyach","year":"2024","unstructured":"Woyach JA, Jones D, Jurczak W et al (2024) Mutational profile in previously treated patients with chronic lymphocytic leukemia progression on acalabrutinib or ibrutinib. Blood 144(10):1061\u20131068","journal-title":"Blood"},{"issue":"1","key":"6775_CR52","doi-asserted-by":"crossref","first-page":"62","DOI":"10.1111\/bjh.18162","volume":"198","author":"Y Song","year":"2022","unstructured":"Song Y, Sun M, Qi J et al (2022) A two-part, single-arm, multicentre, phase I study of zanubrutinib, a selective Bruton tyrosine kinase inhibitor, in Chinese patients with relapsed\/refractory B-cell malignancies. Br J Haematol 198(1):62\u201372","journal-title":"Br J Haematol"},{"issue":"9","key":"6775_CR53","doi-asserted-by":"crossref","first-page":"1929","DOI":"10.1182\/bloodadvances.2022008447","volume":"7","author":"A Naeem","year":"2023","unstructured":"Naeem A, Utro F, Wang Q et al (2023) Pirtobrutinib targets BTK C481S in ibrutinib-resistant CLL but second-site BTK mutations lead to resistance. Blood Adv 7(9):1929\u20131943","journal-title":"Blood Adv"},{"issue":"1","key":"6775_CR54","doi-asserted-by":"publisher","first-page":"35","DOI":"10.1186\/s10020-022-00461-0","volume":"28","author":"C Calissano","year":"2022","unstructured":"Calissano C, Damle RN, Marsilio S et al (2022) Correction to: Intraclonal Complexity in Chronic Lymphocytic Leukemia: Fractions Enriched in Recently Born\/Divided and Older\/Quiescent Cells. Mol Med 28(1):35","journal-title":"Mol Med"},{"issue":"9","key":"6775_CR55","doi-asserted-by":"crossref","first-page":"1022","DOI":"10.1158\/2159-8290.CD-14-0098","volume":"4","author":"D Chiron","year":"2014","unstructured":"Chiron D, Di Liberto M, Martin P et al (2014) Cell-cycle reprogramming for PI3K Inhibition overrides a relapse-specific C481S BTK mutation revealed by longitudinal functional genomics in mantle cell lymphoma[J]. Cancer Discov 4(9):1022\u20131035","journal-title":"Cancer Discov"},{"issue":"4","key":"6775_CR56","doi-asserted-by":"crossref","first-page":"578","DOI":"10.1111\/bjh.15567","volume":"183","author":"P Jain","year":"2018","unstructured":"Jain P, Kanagal-Shamanna R, Zhang S et al (2018) Long-term outcomes and mutation profiling of patients with mantle cell lymphoma (MCL) who discontinued ibrutinib. Br J Haematol 183(4):578\u2013587","journal-title":"Br J Haematol"},{"key":"6775_CR57","doi-asserted-by":"publisher","unstructured":"Polcik L, Dannewitz Prosseda S, Pozzo F et al (2022) Integrin signaling shaping BTK-inhibitor resistance. Cells 11(14):2235. https:\/\/doi.org\/10.3390\/cells11142235","DOI":"10.3390\/cells11142235"},{"issue":"11","key":"6775_CR58","doi-asserted-by":"crossref","first-page":"2590","DOI":"10.1182\/blood-2011-11-390989","volume":"119","author":"MFM de Rooij","year":"2012","unstructured":"de Rooij MFM, Kuil A, Geest CR et al (2012) The clinically active BTK inhibitor PCI-32765 targets B-cell receptor- and chemokine-controlled adhesion and migration in chronic lymphocytic leukemia. Blood 119(11):2590\u20132594","journal-title":"Blood"},{"issue":"8","key":"6775_CR59","doi-asserted-by":"crossref","first-page":"922","DOI":"10.1038\/nm.3884","volume":"21","author":"WH Wilson","year":"2015","unstructured":"Wilson WH, Young RM, Schmitz R et al (2015) Targeting B cell receptor signaling with ibrutinib in diffuse large B cell lymphoma[J]. Nat Med 21(8):922\u2013926","journal-title":"Nat Med"},{"issue":"7332","key":"6775_CR60","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1038\/nature09671","volume":"470","author":"VN Ngo","year":"2011","unstructured":"Ngo VN, Young RM, Schmitz R et al (2011) Oncogenically active MYD88 mutations in human lymphoma[J]. Nature 470(7332):115\u2013119","journal-title":"Nature"},{"issue":"12","key":"6775_CR61","doi-asserted-by":"crossref","first-page":"2794","DOI":"10.1182\/bloodadvances.2022008821","volume":"7","author":"S Bonfiglio","year":"2023","unstructured":"Bonfiglio S, Sutton L, Ljungstr\u00f6m V et al (2023) BTK and PLCG2 remain unmutated in one-third of patients with CLL relapsing on ibrutinib. Blood Adv 7(12):2794\u20132806","journal-title":"Blood Adv"},{"issue":"6","key":"6775_CR62","doi-asserted-by":"crossref","first-page":"833","DOI":"10.1084\/jem.20142009","volume":"212","author":"L Mansouri","year":"2015","unstructured":"Mansouri L, Sutton L, Ljungstr\u00f6m V et al (2015) Functional loss of I\u03baB\u03b5 leads to NF-\u03baB deregulation in aggressive chronic lymphocytic leukemia. J Exp Med 212(6):833\u2013843","journal-title":"J Exp Med"},{"issue":"12","key":"6775_CR63","doi-asserted-by":"crossref","first-page":"1364","DOI":"10.1038\/ni.1678","volume":"9","author":"S Vallabhapurapu","year":"2008","unstructured":"Vallabhapurapu S, Matsuzawa A, Zhang W et al (2008) Nonredundant and complementary functions of TRAF2 and TRAF3 in a ubiquitination cascade that activates NIK-dependent alternative NF-kappaB signaling[J]. Nat Immunol 9(12):1364\u20131370","journal-title":"Nat Immunol"},{"issue":"2","key":"6775_CR64","doi-asserted-by":"crossref","first-page":"448","DOI":"10.3324\/haematol.2019.219550","volume":"105","author":"F Diop","year":"2020","unstructured":"Diop F, Moia R, Favini C et al (2020) Biological and clinical implications of BIRC3 mutations in chronic lymphocytic leukemia[J]. Haematologica 105(2):448\u2013456","journal-title":"Haematologica"},{"issue":"4","key":"6775_CR65","doi-asserted-by":"crossref","first-page":"559","DOI":"10.1002\/cncr.31831","volume":"125","author":"R Kanagal-Shamanna","year":"2019","unstructured":"Kanagal-Shamanna R, Jain P, Patel KP et al (2019) Targeted multigene deep sequencing of Bruton tyrosine kinase inhibitor-resistant chronic lymphocytic leukemia with disease progression and Richter transformation[J]. Cancer 125(4):559\u2013574","journal-title":"Cancer"},{"issue":"5870","key":"6775_CR66","doi-asserted-by":"crossref","first-page":"1676","DOI":"10.1126\/science.1153629","volume":"319","author":"G Lenz","year":"2008","unstructured":"Lenz G, Davis RE, Ngo VN et al (2008) Oncogenic CARD11 mutations in human diffuse large B cell lymphoma. Science 319(5870):1676\u20131679","journal-title":"Science"},{"key":"6775_CR67","doi-asserted-by":"crossref","unstructured":"Xue L, Apatira M, Sirisawad M et al (2015) Abstract 1742: ibrutinib plus proteasome or MALT1 inhibitors overcome resistance to BCR antagonists in CARD11 mutant-expressing B-lymphoma cells. Cancer Res 75(15_Supplement):1742","DOI":"10.1158\/1538-7445.AM2015-1742"},{"issue":"1","key":"6775_CR68","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1038\/nm.3435","volume":"20","author":"R Rahal","year":"2014","unstructured":"Rahal R, Frick M, Romero R et al (2014) Pharmacological and genomic profiling identifies NF-\u03baB-targeted treatment strategies for mantle cell lymphoma[J]. Nat Med 20(1):87\u201392","journal-title":"Nat Med"},{"issue":"18","key":"6775_CR69","doi-asserted-by":"crossref","first-page":"2519","DOI":"10.1182\/blood-2017-01-761726","volume":"129","author":"L Xu","year":"2017","unstructured":"Xu L, Tsakmaklis N, Yang G et al (2017) Acquired mutations associated with ibrutinib resistance in Waldenstr\u00f6m macroglobulinemia[J]. Blood 129(18):2519\u20132525","journal-title":"Blood"},{"issue":"7","key":"6775_CR70","doi-asserted-by":"crossref","first-page":"1222","DOI":"10.1182\/blood-2012-12-475111","volume":"122","author":"G Yang","year":"2013","unstructured":"Yang G, Zhou Y, Liu X et al (2013) A mutation in MYD88 (L265P) supports the survival of lymphoplasmacytic cells by activation of Bruton tyrosine kinase in Waldenstr\u00f6m macroglobulinemia[J]. Blood 122(7):1222\u20131232","journal-title":"Blood"},{"issue":"11","key":"6775_CR71","first-page":"2489","volume":"6","author":"H Kuo","year":"2016","unstructured":"Kuo H, Ezell SA, Hsieh S et al (2016) The role of PIM1 in the ibrutinib-resistant ABC subtype of diffuse large B-cell lymphoma[J]. Am J Cancer Res 6(11):2489\u20132501","journal-title":"Am J Cancer Res"},{"issue":"1","key":"6775_CR72","volume":"5","author":"J Fares","year":"2020","unstructured":"Fares J, Fares MY, Khachfe HH et al (2020) Molecular principles of metastasis: a hallmark of cancer revisited. Signal Transduct Target Ther 5(1):28","journal-title":"Signal Transduct Target Ther"},{"key":"6775_CR73","first-page":"2","volume":"8","author":"J Xie","year":"2025","unstructured":"Xie J, Lin X, Deng X et al (2025) Cancer-associated fibroblast-derived extracellular vesicles: regulators and therapeutic targets in the tumor microenvironment[J]. Cancer Drug Resist 8:2","journal-title":"Cancer Drug Resist"},{"key":"6775_CR74","doi-asserted-by":"crossref","unstructured":"Brown J, Mashima K, Fernandes S et al (2024) Mutations detected in real world clinical sequencing during BTK inhibitor treatment in CLL[J]. Res Sq 16(27):124","DOI":"10.21203\/rs.3.rs-3837426\/v1"},{"issue":"6","key":"6775_CR75","doi-asserted-by":"crossref","first-page":"1413","DOI":"10.3109\/10428194.2015.1113276","volume":"57","author":"JH Kim","year":"2016","unstructured":"Kim JH, Kim WS, Ryu K et al (2016) CD79B limits response of diffuse large B cell lymphoma to ibrutinib[J]. Leuk Lymphoma 57(6):1413\u20131422","journal-title":"Leuk Lymphoma"},{"key":"6775_CR76","doi-asserted-by":"crossref","first-page":"3109","DOI":"10.1182\/blood-2022-169574","volume":"140","author":"O Kersy","year":"2022","unstructured":"Kersy O, Salmon-Divon M, Gomes Da Silva M et al (2022) Inhibition of MAPK-ERK signaling pathway overcomes Microrna-Mediated ibrutinib resistance in mantle cell Lymphoma[J]. Blood 140:3109\u20133110","journal-title":"Blood"},{"key":"6775_CR77","doi-asserted-by":"publisher","unstructured":"Spinosa PC, Humphries BA, Lewin Mejia D et al (2019) Short-term cellular memory tunes the signaling responses of the chemokine receptor CXCR4. Sci Signal 12(589):4204. https:\/\/doi.org\/10.1126\/scisignal.aaw4204","DOI":"10.1126\/scisignal.aaw4204"},{"issue":"1","key":"6775_CR78","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1038\/leu.2014.187","volume":"29","author":"Y Cao","year":"2015","unstructured":"Cao Y, Hunter ZR, Liu X et al (2015) The WHIM-like CXCR4(S338X) somatic mutation activates AKT and ERK, and promotes resistance to ibrutinib and other agents used in the treatment of waldenstrom\u2019s Macroglobulinemia[J]. Leukemia 29(1):169\u2013176","journal-title":"Leukemia"}],"container-title":["Annals of Hematology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00277-026-06775-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00277-026-06775-x","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00277-026-06775-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,17]],"date-time":"2026-04-17T05:58:39Z","timestamp":1776405519000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00277-026-06775-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,2,21]]},"references-count":78,"journal-issue":{"issue":"4","published-online":{"date-parts":[[2026,4]]}},"alternative-id":["6775"],"URL":"https:\/\/doi.org\/10.1007\/s00277-026-06775-x","relation":{},"ISSN":["1432-0584"],"issn-type":[{"value":"1432-0584","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,2,21]]},"assertion":[{"value":"3 August 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"1 December 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"21 February 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"132"}}